ArticleCurrent microbiology2014
Characterization of secondary metabolites of an endophytic fungus from Curcuma wenyujin.
Article in Current microbiology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- An Update of Fungal Endophyte Diversity and Strategies for Augmenting Therapeutic Potential of their Potent Metabolites: Recent Advancement.Applied biochemistry and biotechnology · 2025Review
- Genus Curcuma: chemical and ethnopharmacological role in aging process.BMC complementary medicine and therapies · 2024Review
- Comparative analysis of antimicrobial compounds from endophytic Buergenerula spartinae from orchid.Antonie van Leeuwenhoek · 2023Article
- Exploration of the Specific Pathology of HXMM Tablet Against Retinal Injury Based on Drug Attack Model to Network Robustness.Frontiers in pharmacology · 2022Article
- Fungal Endophytes as Efficient Sources of Plant-Derived Bioactive Compounds and Their Prospective Applications in Natural Product Drug Discovery: Insights, Avenues, and Challenges.Microorganisms · 2021Review
- An endophytic Coniochaeta velutina producing broad spectrum antimycotics.Journal of microbiology (Seoul, Korea) · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Endophytic fungi are ubiquitous in the plant kingdom and they produce a variety of secondary metabolites to protect plant communities and to show some potential for human use. However, secondary metabolites produced by endophytic fungi in the medicinal plant Curcuma wenyujin are sparsely explored and characterized. The aim of this study was to characterize the secondary metabolites of an active endophytic fungus. M7226, the mutant counterpart of endophytic fungus EZG0807 previously isolated from the root of C. wenyujin, was as a target strain. After fermentation, the secondary metabolites were purified using a series of purification methods including thin layer chromatography, column chromatography with silica, ODS-C18, Sephadex LH-20, and macroporous resin, and were analyzed using multiple pieces of data (UV, IR, MS, and NMR). Five compounds were isolated and identified as curcumin, cinnamic acid, 1,4-dihydroxyanthraquinone, gibberellic acid, and kaempferol. Interestingly, curcumin, one of the main active ingredients of C. wenyujin, was isolated as a secondary metabolite from a fungal endophyte for the first time.
Indexed as
Identifiers
25002358What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.